Managing stage 3 chronic kidney disease in primary care

Managing stage 3 chronic kidney disease in primary care

Stage 3 chronic kidney disease (CKD) is estimated to affect over 30 million adults in the United States. Patients with advanced CKD, defined for our purposes as stage 4 and 5, will often have ongoing follow ups with a nephrologist. However, in CKD stage 3 (defined as eGFR 30-59mL/min) the PCP will often be at the helm of treatment. Managing CKD stage 3 can be complex, having a clinical pharmacist meet with your CKD patients prior to their office visit helps to prepare both the patient and you to have the most comprehensive and efficient visit possible.

Cost/benefit of direct oral anticoagulants

Cost/benefit of direct oral anticoagulants

More than 5 million people in the U.S. have atrial fibrillation, leading to an increased risk of stroke and related heart problems. Here’s a cost/benefit analysis of some of the leading medication options for treating this prevalent condition and the role of PGx.